Mindful Medical Research

San Juan 00918

0 studies enrolling now · 15 studies all time

What they study most

Alzheimer Disease, Arthritis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Autoimmune Diseases, Cardiovascular Diseases, Chronic Kidney Disease, Connective Tissue Diseases, Diffuse Cutaneous Systemic Sclerosis, Immune System Diseases, Joint Diseases, Lupus Erythematosus, Systemic

Studies at this site

• Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis — Stopped early
• A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus — Stopped early
• Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis — Paused
• Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis — Completed
• A Study in Moderate to Severe Rheumatoid Arthritis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) — Completed
• A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus — Stopped early